Related Experiment Video

Updated: May 26, 2026

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing
05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Adding to the mix: fibroblast growth factor and platelet-derived growth factor receptor pathways as targets in

S A Kono1, L E Heasley, R C Doebele

  • 1Aerodigestive and Thoracic Tumor Program, Winship Cancer Institute, Emory University, Room C3005, 1365 Clifton Road NE, Atlanta, GA 30322, USA. skono@emory.edu

Current Cancer Drug Targets
|December 15, 2011
PubMed

Insights

New targeted therapies for advanced non-small cell lung cancer (NSCLC) focus on fibroblast growth factor receptor (FGFR) and platelet-derived growth factor receptor (PDGFR) pathways. These pathways are crucial for tumor growth, angiogenesis, and resistance to other treatments.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Advanced non-small cell lung cancer (NSCLC) treatment increasingly utilizes molecularly targeted therapies.
  • Vascular endothelial growth factor (VEGF) pathway is a key target for anti-angiogenesis, with bevacizumab as an approved agent.
  • Emerging research highlights the roles of fibroblast growth factor receptor (FGFR) and platelet-derived growth factor receptor (PDGFR) signaling in tumor growth and angiogenesis.

Purpose of the Study:

  • To review the molecular roles of PDGFR and FGFR in tumor growth and angiogenesis in NSCLC.
  • To discuss the potential of targeting PDGF and FGF pathways in NSCLC treatment.
  • To summarize the clinical development status of PDGFR and FGFR inhibitors for NSCLC.

Main Methods:

  • Literature review of preclinical and clinical studies.
  • Analysis of signaling pathways involved in angiogenesis and tumor growth.
  • Summary of ongoing clinical trials for FGFR and PDGFR inhibitors.

Main Results:

  • FGFR and PDGFR signaling pathways contribute to tumor growth and angiogenesis.
  • These pathways may also drive resistance to existing therapies like EGFR and VEGF inhibitors.
  • Several agents targeting FGF and/or PDGF signaling are currently in clinical development for NSCLC.

Conclusions:

  • Targeting FGFR and PDGFR represents a promising strategy for advanced NSCLC.
  • Inhibitors of these pathways may overcome resistance mechanisms and improve treatment outcomes.
  • Further clinical investigation of PDGFR and FGFR inhibitors is warranted for NSCLC patients.

More Related Videos

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Related Concept Videos

Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...